Table 4.
Agent | Target | Clinical Trial | Cancer Type | Primary Objective |
---|---|---|---|---|
CA-170 Trial IDs: CTRI/2017/12/011026 (phase II) CTRI/2020/07/026870 (phase IIb/III) |
PD-L1 | Phase II | Lymphoma | ORR: 30% |
PD-L1 | Phase IIb/III | Non-squamous, non-small cell lung cancer | ORR: ongoing | |
INCB086550 Trial ID: NCT04629339 |
PD-L1 | Phase II | Select solid tumors | ORR: ongoing |
CCX559 Trial ID: ACTRN12621001342808 |
PD-L1 | Phase I | Solid tumors | Safety |